PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/NON-RI) - AstraZeneca Plc

21 May 2014 14:52

RNS Number : 7255H
JPMorgan Securities Plc
21 May 2014
 



FORM 8.5 (EPT/NON-RI)

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY AN

EXEMPT PRINCIPAL TRADER WITHOUT RECOGNISED INTERMEDIARY ("RI") STATUS (OR WHERE RI STATUS IS NOT APPLICABLE)

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

J.P. Morgan Securities Plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

AstraZeneca Plc

(c) Name of the party to the offer with which exempt principal trader is connected:

Pfizer Inc.

(d) Date position held/dealing undertaken:

19 May 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

NO

 

2. POSITIONS OF THE EXEMPT PRINCIPAL TRADER

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

931,106

0.07%

885,000

0.07%

(2) Derivatives (other than options):

(3) Options and agreements to purchase/sell:

 

TOTAL:

 

931,106

 

0.07%

 

885,000

 

0.07%

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other executive options)

 

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

3. DEALINGS (IF ANY) BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

Ordinary Shares traded as ADRs

 

 

 

 

 

Ordinary Shares

 

 

 

 

 

Purchases

 

 

 

 

 

 

Sales

 

200,000

100,000

350,000

150,000

50,000

35,000

 

200,000

100,000

350,000

150,000

50,000

35,000

 

 

70.1885 USD

70.4098 USD

70.7917 USD

72.0814 USD

72.9213 USD

74.0164 USD

 

41.7450 GBP

41.8876 GBP

42.0900 GBP

42.8750 GBP

43.3500 GBP

44.0000 GBP

 

(b) Derivatives transactions (other than options)

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercising

 

Class of relevant security

Product description

e.g. call option

Number of securities

Exercise price per unit

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

 

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

NO

 

 

Date of disclosure:

21 May 2014

Contact name:

Michael Kirwan

Telephone number:

020 7134 6153

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEOXFLFLZEFEBBF
Date   Source Headline
14th Mar 201912:00 pmRNSNotice of AGM
12th Mar 201912:00 pmRNSDirector/PDMR Shareholding
6th Mar 20197:00 amRNSFiling of Form 20-F with SEC
5th Mar 201911:00 amRNSAnnual Financial Report
4th Mar 20194:04 pmRNSHolding(s) in Company
1st Mar 20193:00 pmRNSTotal Voting Rights
1st Mar 20191:45 pmRNSLynparza receives positive EU CHMP opinion
26th Feb 20197:00 amRNSLynparza significantly delayed disease progression
25th Feb 20197:00 amRNSBrilinta's PhIII THEMIS trial met primary endpoint
14th Feb 20197:00 amRNSAstraZeneca Full-Year and Q4 2018 Results
6th Feb 20197:00 amRNSUS FDA grants Fasenra Orphan Drug Designation
5th Feb 20197:05 amRNSUS FDA grants Breakthrough Therapy Designation
5th Feb 20197:00 amRNSEMA grants PRIME eligibility for MEDI8897
1st Feb 20193:00 pmRNSTotal Voting Rights
1st Feb 20191:17 pmRNSForxiga receives positive EU CHMP opinion
25th Jan 20192:00 pmRNSCompletion of divestment of US Synagis rights
7th Jan 20191:00 pmRNSAstraZeneca announces organisational changes
2nd Jan 20193:00 pmRNSTotal Voting Rights
20th Dec 20181:47 pmRNSBevespi Aerosphere approved in the EU for COPD
20th Dec 20187:05 amRNSLynparza meets primary endpoint in SOLO-3 trial
20th Dec 20187:00 amRNSPhase III ROCKIES and OLYMPUS roxadustat trials
19th Dec 20186:31 pmRNSFDA approves Lynparza as 1L maintenance therapy
18th Dec 20189:09 amRNSRoxadustat approved in China for the treatment of
14th Dec 20187:00 amRNSDirectorate Change
7th Dec 20187:00 amRNSUpdate on the Phase III EAGLE trial of Imfinzi
6th Dec 20187:00 amRNSDivestment of rights to Covis completed
4th Dec 20183:00 pmRNSDirector/PDMR Shareholding
3rd Dec 20184:00 pmRNSBlock listing Interim Review
3rd Dec 20184:00 pmRNSTotal Voting Rights
3rd Dec 20187:00 amRNSGrünenthal Agreement for Nexium, Vimovo Completed
26th Nov 20187:00 amRNSUS FDA grants Fasenra ODD for EGPA
16th Nov 20187:00 amRNSAstraZeneca provides update on Phase III MYSTIC
13th Nov 20187:00 amRNSAstraZeneca to divest US Synagis rights to Sobi
12th Nov 20187:05 amRNSUS FDA accepts regulatory submission for Lynparza
12th Nov 20187:00 amRNSFarxiga significantly reduced hospitalisation for
8th Nov 20187:00 amRNSAZN: Year-to-Date and Q3 2018 Results
6th Nov 20187:00 amRNSDivestment of rights to Covis Pharma
1st Nov 20183:00 pmRNSTotal Voting Rights
31st Oct 20189:45 amRNSAdditional financial information-Grünenthal deal
30th Oct 20187:00 amRNSGrünenthal Agreement for rights to Nexium, Vimovo
23rd Oct 20187:00 amRNSAstraZeneca Extends Innate Pharma Collaboration
22nd Oct 20187:00 amRNSLynparza shows 70% reduction in PFS ovarian cancer
19th Oct 20181:09 pmRNSCHMP positive opinion Bevespi Aerosphere
16th Oct 20187:00 amRNSFDA Orphan Drug for Lynparza in pancreatic cancer
1st Oct 20183:00 pmRNSTotal Voting Rights
1st Oct 20187:00 amRNSAtacand Agreement with Cheplapharm Completed
28th Sep 20184:00 pmRNSPrevious Announcement Regarding Appointment Of NED
25th Sep 20181:15 pmRNSOverall survival data for Imfinzi: Stage III NSCLC
24th Sep 20184:10 pmRNSEMA approves AZ's Imfinzi for Stage III NSCLC
24th Sep 20187:00 amRNSFarxiga gets positive result in DECLARE-TIMI 58

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.